Richard Daniell
Known title: Exec. VP, European CommercialCIK: 0001726096
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 30,000 | $1.1M | 5/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 17,295 | — | 3/5/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 17,295 | $548K | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 33,512 | $1.1M | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 20,461 | $664K | 3/4/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 37,372 | $1.2M | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 62,250 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 62,250 | $2.0M | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 66,735 | $2.2M | 3/3/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 115,468 | $3.3M | 12/9/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 100,457 | $1.9M | 12/9/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,011 | $255K | 12/9/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 48,385 | $769K | 3/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 22,576 | $359K | 3/5/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 11,641 | $185K | 3/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 7,108 | $113K | 3/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 30,015 | $478K | 3/5/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 21,870 | $344K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,461 | — | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 13,353 | $210K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 183,169 | — | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 56,385 | $887K | 3/4/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 12,936 | $201K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 62,250 | — | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 49,314 | $798K | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 98,943 | $1.7M | 8/12/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 22,576 | $305K | 3/5/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 55,226 | — | 3/5/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 26,053 | $352K | 3/5/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 62,250 | $830K | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 33,512 | $447K | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 62,250 | — | 3/3/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,599 | — | 2/28/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 20,599 | $270K | 2/28/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 54,007 | $509K | 3/7/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 18,002 | $179K | 3/6/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,921 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,598 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 20,598 | $204K | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 50,242 | — | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 23,654 | $234K | 2/28/2023 | View on chart |
| TEVA | ▼ Sell | Open Market | 22,576 | $166K | 3/7/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 22,576 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,920 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 15,920 | $119K | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 43,358 | — | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 20,456 | $153K | 3/4/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 20,598 | $168K | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,598 | — | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 13,135 | — | 2/9/2022 | View on chart |
| TEVA | ▼ Sell | Open Market | 13,135 | $119K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.